Rho-Kinase-IN-2 (Compound 23) 是一种具有口服活性的、选择性的和中枢神经系统 (CNS) 渗透性的 Rho激酶 (ROCK) 抑制剂 (ROCK2 IC50=3 nM)。Rho-Kinase-IN-2 可用于亨廷顿病的研究。
| Cas No. | 2573071-18-6 |
| 分子式 | C20H25FN4O2 |
| 分子量 | 372.44 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端
描述 | Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington's research[1]. Rho-Kinase-IN-2 (0-10 mM, 1 hour) treatment shows an increase in AKT phosphorylation and a decrease in MYPT1 phosphorylation[1]. Western Blot Analysis[1] | Cell Line: | A7r5 and PANC1 cells | | Concentration: | 0-10 mM | | Incubation Time: | 1 hour | | Result: | Showed concentration-dependent effects, leading to an increase in AKT phosphorylation (EC50=28 nM) and a decrease in MYPT1 phosphorylation (IC50=14 nM). |
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h) treatment shows dose- and time-dependent ROCK1 and ROCK2 target engagement[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; QD or BID; 2 weeks) treatment shows excellent tolerability assessment[1].
Rho-Kinase-IN-2 (oral adiministration; 1-20 mg/kg; once) treatment shows a direct dose- and time-dependent relationship between brain exposure and MYPT1 phosphorylation status[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; once) treatment decreases in the mean arterial, systolic, diastolic blood pressure, and heart rate[1].
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; twice a day; 90 days) treatment leads to lower-than-expected brain concentrations[1]. | Animal Model: | Male C57BL/6 mice[1] | | Dosage: | 10 mg/kg | | Administration: | Oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h | | Result: | Observed dose- and time-dependent ROCK1 and ROCK2 TE, with a free brain KiNativ ROCK1 and ROCK2 IC50=∼6 nM. |
| Animal Model: | 3-4 months old heterozygote Q175DN KI and wild-type littermate mice[1] | | Dosage: | 10 or 20 mg/kg | | Administration: | Oral adiministration; 10 or 20 mg/kg; once a day or twice a day; 2 weeks | | Result: | Scored neurological index normally at all doses although a slight loss in bodyweight (∼2%) in the 20 mg/kg treatment group. |
| Animal Model: | Heterozygote HTT zQ175DN knock-in mice[1] | | Dosage: | 1-20 mg/kg | | Administration: | Oral adiministration; 1-20 mg/kg; once | | Result: | Remained over MYPT1 IC50for over 2 h of the free brain at 10 mg/kg, and observed the dose- and time-dependent inhibition of MYPT1 phosphorylation in the striatum following acute in vivo dosing. |
| Animal Model: | CD1 mice[1] | | Dosage: | 10 and 20 mg/kg | | Administration: | Oral adiministration; 10 or 20 mg/kg; once | | Result: | Observed the decreases in the mean arterial (maximum change of 61.0 ± 8.5 mmHg from baseline), systolic (maximum change of 59.5 ± 8.4 mmHg from baseline), diastolic blood pressure (maximum change of 56.4 ± 9.0 mmHg from baseline), and heart rate (maximum change from predose of 107 bpm) when compared to the control group from ∼0.5 to 2 h post dose. |
| Animal Model: | Heterozygote Q175DN KI mouse model of HD[1] | | Dosage: | 10 mg/kg | | Administration: | Oral adiministration; 10 mg/kg; twice a day; 90 days | | Result: | Led to lower-than-expected brain concentrations compared to single dosing. |
|
m.cnreagent.com